Vanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023PRNewsWire • 11/01/23
Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA LitigationPRNewsWire • 10/20/23
Vanda Pharmaceuticals Announces Participation in the Jefferies Inaugural Biotech CNS/Neuro SummitPRNewsWire • 10/05/23
After Plunging -7.98% in 4 Weeks, Here's Why the Trend Might Reverse for Vanda (VNDA)Zacks Investment Research • 09/01/23
5 Biotech Stocks to Buy as New Drug Approvals Drive Industry ProspectsZacks Investment Research • 09/01/23
Vanda Pharmaceuticals to Announce Second Quarter 2023 Financial Results on July 27, 2023PRNewsWire • 07/20/23
Vanda Pharmaceuticals Announces Participation in the Jefferies 2023 Global Healthcare ConferencePRNewsWire • 06/05/23
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2SPRNewsWire • 06/02/23
Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion SicknessPRNewsWire • 05/25/23
Vanda Pharmaceuticals Sues Federal Government for Misappropriation of Trade Secrets and Confidential InformationPRNewsWire • 05/02/23
Vanda Pharmaceuticals to Announce First Quarter 2023 Financial Results on May 3, 2023PRNewsWire • 04/27/23